文献速递甲状腺疾病

纳武利尤单抗诱导甲状腺炎的临床特征:病例系列研究

Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
PubMed 文献 · Thyroid · 2017-06-21

该病例系列分析了5例纳武利尤单抗相关甲状腺功能障碍患者,均诊断为无痛性甲状腺炎,其中3例在首次给药4周内出现甲状腺毒症并在起病4周内恢复正常,2例在短暂甲状腺毒症后出现甲减,1例原有甲减持续。研究还证实正常甲状腺组织表达PD-L1和PD-L2 mRNA及蛋白。作者提出仅对症治疗甲状腺毒症、后续甲减时考虑左甲状腺素替代治疗。

要点

  • 纳武利尤单抗诱导的甲状腺毒症似与无痛性甲状腺炎相关,未观察到Graves病患者。
  • 5例患者均诊断为无痛性甲状腺炎,甲状腺毒症多在首次给药4周内出现。
  • 正常甲状腺组织表达PD-L1和PD-L2 mRNA及蛋白,提示纳武利尤单抗可能降低正常甲状腺组织的免疫耐受。

核心结论

  • 纳武利尤单抗诱导的甲状腺毒症似与无痛性甲状腺炎相关,未观察到Graves病患者。
  • 纳武利尤单抗诱导的甲状腺炎呈短暂快速病程并后续出现甲减。
  • 正常甲状腺组织表达PD-L1和PD-L2,提示纳武利尤单抗治疗降低正常甲状腺组织的免疫耐受并导致甲状腺炎发生。
  • 作者提出仅对症治疗甲状腺毒症,后续出现甲减时考虑左甲状腺素替代治疗。
  • 需进一步研究以确认糖皮质激素治疗和停用纳武利尤单抗是否能预防后续甲减。

研究设计与样本

  • 分析5例连续接受纳武利尤单抗治疗后出现甲状腺功能障碍的病例。
  • 采用逆转录聚合酶链反应和Western blotting检测PD-L1和PD-L2的mRNA及蛋白表达。

主要发现

  • 所有患者均诊断为无痛性甲状腺炎。
  • 5例患者中3例在首次纳武利尤单抗给药4周内出现甲状腺毒症,并在起病4周内恢复正常。
  • 2例在短暂甲状腺毒症后出现甲减,1例原有甲减持续。
  • 另2例接受糖皮质激素治疗并因合并不良事件停用纳武利尤单抗,其中1例未出现甲减,另1例出现轻度短暂甲减。
  • 正常甲状腺组织表达PD-L1和PD-L2 mRNA及相应蛋白。

临床怎么用

  • 作者提出仅对症治疗甲状腺毒症,后续出现甲减时考虑左甲状腺素替代治疗。
  • 作者认为需进一步研究以确认糖皮质激素治疗和停用纳武利尤单抗是否能预防后续甲减。

局限性

  • 原文未报告局限性。
  • 作者指出需进一步研究以确认糖皮质激素治疗和停用纳武利尤单抗是否能预防后续甲减。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The programmed cell death-1 (PD-1) pathway is a novel therapeutic target in immune checkpoint therapy for cancer. It consists of the PD-1 receptor and its two ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Nivolumab is an anti-PD-1 monoclonal antibody approved for malignant melanoma, advanced non-small cell lung cancer, and advanced renal cell carcinoma in Japan. Thyrotoxicosis and hypothyroidism have both been reported in international Phase 3 studies and national post-marketing surveillance of nivolumab in Japan. METHODS: This study analyzed five consecutive cases with thyroid dysfunction associated with nivolumab therapy. Second, it examined the mRNA and protein expressions of PD-L1 and PD-L2 by reverse transcription polymerase chain reaction and Western blotting. RESULTS: All patients were diagnosed with painless thyroiditis. Thyrotoxicosis developed within four weeks from the first administration of nivolumab and normalized within four weeks of onset in three of the five patients. Hypothyroidism after transient thyrotoxicosis developed in two patients, and preexisting hypothyroidism persisted in one patient. The other two patients were treated with glucocorticoids and discontinued nivolumab therapy for comorbid adverse events. One did not develop hypothyroidism, and the other developed mild, transient hypothyroidism. In addition, it was verified that normal thyroid tissue expresses PD-L1 and PD-L2 mRNA and those proteins. CONCLUSIONS: In the present cases, nivolumab-induced thyrotoxicosis seemed to be associated with painless thyroiditis, while no patient with Graves' disease was observed. A transient and rapid course with subsequent hypothyroidism was observed in nivolumab-induced thyroiditis. In addition, it was verified that PD-L1 and PD-L2 are expressed in normal thyroid tissue. This suggests that nivolumab therapy reduces immune tolerance, even in normal thyroid tissue, and leads to the development of thyroiditis. Treating thyrotoxicosis with only supportive care and considering levothyroxine replacement therapy once subsequent hypothyroidism occurs is proposed. Further investigations are required to confirm whether glucocorticoid therapy and discontinuation of nivolumab therapy prevent subsequent hypothyroidism.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Thyroid. 2017. PMID: 28537531. doi:10.1089/thy.2016.0562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。